S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
U.S. Military Defense Fails Without Vanadium? (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
U.S. Military Defense Fails Without Vanadium? (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
U.S. Military Defense Fails Without Vanadium? (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
U.S. Military Defense Fails Without Vanadium? (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Sensei Biotherapeutics Stock Price, News & Analysis (NASDAQ:SNSE)

$0.72
+0.04 (+5.93%)
(As of 12/5/2023 ET)
Compare
Today's Range
$0.68
$0.77
50-Day Range
$0.53
$0.82
52-Week Range
$0.51
$1.93
Volume
55,868 shs
Average Volume
48,111 shs
Market Capitalization
$17.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Sensei Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
459.4% Upside
$4.00 Price Target
Short Interest
Healthy
1.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.38
Upright™ Environmental Score
News Sentiment
0.00mentions of Sensei Biotherapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$425 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.24) to ($1.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

90th out of 948 stocks

Pharmaceutical Preparations Industry

26th out of 421 stocks


SNSE stock logo

About Sensei Biotherapeutics Stock (NASDAQ:SNSE)

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

SNSE Stock Price History

SNSE Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
SNSE - Sensei Biotherapeutics, Inc.
Citigroup Remains a Buy on Sensei Biotherapeutics (SNSE)
See More Headlines
Receive SNSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/26/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNSE
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+459.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-48,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.37 per share

Miscellaneous

Free Float
18,623,000
Market Cap
$17.87 million
Optionable
Not Optionable
Beta
0.01
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. John K. Celebi M.B.A. (Age 51)
    President, CEO & Director
    Comp: $799.69k
  • Ms. Erin Colgan (Age 42)
    Chief Financial Officer
    Comp: $558.83k
  • Dr. Edward Van der Horst Ph.D. (Age 50)
    Chief Scientific Officer
    Comp: $444.87k
  • Ms. Lora Pike
    Vice President of Investor Relations & Communications
  • Mr. Christopher W. Gerry J.D.
    General Counsel & Secretary
  • Ms. Stephanie Krebs M.B.A.
    M.S., Chief Business Officer














SNSE Stock Analysis - Frequently Asked Questions

Should I buy or sell Sensei Biotherapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNSE shares.
View SNSE analyst ratings
or view top-rated stocks.

What is Sensei Biotherapeutics' stock price target for 2024?

2 Wall Street analysts have issued twelve-month target prices for Sensei Biotherapeutics' shares. Their SNSE share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 459.4% from the stock's current price.
View analysts price targets for SNSE
or view top-rated stocks among Wall Street analysts.

How have SNSE shares performed in 2023?

Sensei Biotherapeutics' stock was trading at $1.49 on January 1st, 2023. Since then, SNSE shares have decreased by 52.0% and is now trading at $0.7150.
View the best growth stocks for 2023 here
.

Are investors shorting Sensei Biotherapeutics?

Sensei Biotherapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 168,800 shares, an increase of 25.6% from the October 31st total of 134,400 shares. Based on an average daily volume of 47,200 shares, the days-to-cover ratio is presently 3.6 days. Approximately 1.0% of the shares of the company are sold short.
View Sensei Biotherapeutics' Short Interest
.

When is Sensei Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our SNSE earnings forecast
.

How were Sensei Biotherapeutics' earnings last quarter?

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) released its earnings results on Tuesday, November, 7th. The company reported ($0.28) EPS for the quarter, meeting analysts' consensus estimates of ($0.28).

When did Sensei Biotherapeutics IPO?

(SNSE) raised $100 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO.

Who are Sensei Biotherapeutics' major shareholders?

Sensei Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Newtyn Management LLC (7.20%). Insiders that own company stock include Apeiron Investment Group Ltd, Cambrian Biopharma Inc, James Peyer, John Celebi, Robert Hamilton Pierce and Thomas G Ricks.
View institutional ownership trends
.

How do I buy shares of Sensei Biotherapeutics?

Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SNSE) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -